NEW YORK (GenomeWeb News) — DioGenix announced today that it raised $3.2 million in a private financing that will support an ongoing prospective clinical trial of its next generation sequencing-based multiple sclerosis test, MS Precise.

The financing involved both new and returning individual investors, the company said, including life sciences fund Nerveda, whose president, Cam Gallagher, is also chairman of DioGenix. Other investors were not named.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Cell this week: dynamics of protein profusion and localization, melanoma classification schemes, and more.

A company says it can generate likenesses of people based on their genetic profiles.

IBM's Watson is learning how to treat leukemia as a fellow at the MD Anderson Cancer Center, according to the Washington Post.

In PNAS this week: ancestry and admixture in Brazilians, characterization of novel double-stranded RNA mycovirus, and more.